Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (102)
  • Open Access

    ARTICLE

    MicroRNA-204 Inhibits the Growth and Motility of Colorectal Cancer Cells by Downregulation of CXCL8

    Feng Shuai*, Bo Wang, Shuxiao Dong

    Oncology Research, Vol.26, No.8, pp. 1295-1305, 2018, DOI:10.3727/096504018X15172747209020

    Abstract Among all of the miRNAs, miR-204 has gained considerable attention in the field of cancer research. This study aimed to reveal the detailed functions and the underlying mechanism of miR-204 in colorectal cancer (CRC) cells. The expressions of miR-204 in CRC tumor tissues and cell lines were monitored. Expressions of miR-204 and CXCL8 in Caco-2 and HT-29 cells were altered by transfection, and then cell viability, apoptosis, migration, invasion, EMT-related protein expression, and PI3K/AKT/mTOR pathway protein expression were assessed. We found that miR-204 was expressed at low levels in CRC tumor tissues and cell lines… More >

  • Open Access

    ARTICLE

    miR-1290 Contributes to Colorectal Cancer Cell Proliferation by Targeting INPP4B

    Qingzhu Ma*, Yan Wang, Hualing Zhang*, Fengqiang Wang

    Oncology Research, Vol.26, No.8, pp. 1167-1174, 2018, DOI:10.3727/096504017X15051741798389

    Abstract Colorectal cancer (CRC) is one of the most common oncological conditions worldwide, to date. MicroRNA- 1290 (miR-1290) has been demonstrated to regulate its progression. We studied the role of miR-1290 in CRC progression. The gene was upregulated in CRC tissues and cells. Its overexpression promoted CRC cell proliferation analyzed by MTT assay, colony formation assay, and soft agar growth assay. In addition, miR-1290 knockdown inhibited CRC cell proliferation. We also found that miR-1290 overexpression reduced the p27 level and increased cyclin D1 at both the mRNA and protein levels, whereas miR-1290 knockdown increased p27 and More >

  • Open Access

    ARTICLE

    miR-522-3p Promotes Tumorigenesis in Human Colorectal Cancer via Targeting Bloom Syndrome Protein

    Feng Shuai*, Bo Wang, Shuxiao Dong

    Oncology Research, Vol.26, No.7, pp. 1113-1121, 2018, DOI:10.3727/096504018X15166199939341

    Abstract miR-522-3p is known to degrade bloom syndrome protein (BLM) and enhance expression of other proto-oncogenes, leading to tumorigenesis. This study aimed to investigate the molecular mechanisms of miR-522-3p in human colorectal cancer (CRC) cells. Expressions of miR-522-3p in CRC and adjacent tissues, as well as in normal human colon epithelial cell line (FHC) and five CRC cell lines, were detected. Human CRC cell lines, HCT-116 and HT29, were transfected with miR-522-3p mimic, inhibitor, or scrambled controls. Then cell viability, apoptosis, cell cycle progression, and the expressions of c-myc, cyclin E, CDK2, and BLM were assessed.… More >

  • Open Access

    ARTICLE

    Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients

    Yuping Shen, Chunyan Li, Weixing Liu, Wei Mao, Hong Qian, Hui Wang, Qing Xu

    Oncology Research, Vol.26, No.5, pp. 801-807, 2018, DOI:10.3727/096504017X15139039328978

    Abstract This study investigated the characteristics of oxaliplatin-induced hypersensitivity reactions (HSRs) and evaluated the efficacy of premedication for controlling HSRs among colorectal cancer patients. A retrospective study was performed on the clinical records of 291 patients with colorectal cancer in The Tenth People’s Hospital of Shanghai from January 2008 to January 2016. Patients who experienced HSRs to oxaliplatin were compared with those who did not. A total of 291 colorectal cancer patients received oxaliplatin, with 39 (13.40%) experiencing HSRs. Oxaliplatin-free interval and premedication with dexamethasone and antihistamine were independent variables for oxaliplatin-related HSRs. Rechallenging patients with More >

  • Open Access

    ARTICLE

    miR-133a-3p Targets SUMO-Specific Protease 1 to Inhibit Cell Proliferation and Cell Cycle Progress in Colorectal Cancer

    Guo-Qiang Zhou*, Fu Han*, Zhi-Liang Shi*, Liang Yu*, Xue-Feng Li*, Cheng Yu*, Cheng-Long Shen*, Dai-Wei Wan, Xin-Guo Zhu, Rui Li, Song-Bing He

    Oncology Research, Vol.26, No.5, pp. 795-800, 2018, DOI:10.3727/096504017X15004613574679

    Abstract Dysregulation of SUMO-specific protease 1 (SENP1) expression has been reported in several kinds of cancer, including human colorectal and prostate cancers, proposing SENP1 as an oncogene with a critical role in cancer progression. miR-133a-3p has been reported as a tumor suppressor in several malignant neoplasias. However, the precise molecular mechanisms underlying its role in colorectal cancer remain largely unknown. The aim of this work was to investigate the relationship between miR-133a-3p and SENP1 in colorectal cancer cells. We found that miR-133a-3p expression was downregulated in colorectal cancer tissues. In silico analyses indicated that SENP1 is More >

  • Open Access

    ARTICLE

    MicroRNA-520b Functions as a Tumor Suppressor in Colorectal Cancer by Inhibiting Defective in Cullin Neddylation 1 Domain Containing 1 (DCUN1D1)

    Jing Xiao*, Guang Li, Jingyu Zhou, Shalong Wang, Dongcai Liu, Guoshun Shu, Jianping Zhou, Feng Ren

    Oncology Research, Vol.26, No.4, pp. 593-604, 2018, DOI:10.3727/096504017X14920318811712

    Abstract MicroRNAs (miRs), a class of small noncoding RNAs, are important regulators for gene expression through directly binding to the 3'-untranslated region (3'-UTR) of their target mRNA. Recently, downregulation of miR-520b has been observed in several common human cancers. However, the exact role of miR-520b in colorectal cancer (CRC) has not previously been studied. In this study, our data showed that miR-520b was significantly downregulated in CRC and cell lines when compared with adjacent normal tissues and a normal intestinal epithelial cell line. Low expression of miR-520b was notably associated with the malignant progress and a… More >

  • Open Access

    ARTICLE

    The Long Noncoding RNA HOTAIR Promotes Colorectal Cancer Progression by Sponging miR-197

    Xinyang Lu, Zhiqiang Liu, Xiaofei Ning, Lunhua Huang, Biao Jiang

    Oncology Research, Vol.26, No.3, pp. 473-481, 2018, DOI:10.3727/096504017X15105708598531

    Abstract The long noncoding RNA HOX transcript antisense RNA (HOTAIR) has been found to be overexpressed in many human malignancies and involved in tumor progression and metastasis. Although the downstream target through which HOTAIR modulates tumor metastasis is not well known, evidence suggests that microRNA-197 (miR-197) might be involved in this event. In the present study, the significance of HOTAIR and miR-197 in the progression of colorectal cancer was detected in vitro and in vivo. We found that HOTAIR expression was significantly increased in colorectal cancer cells and tissues. In contrast, the expression of miR-197 was More >

  • Open Access

    ARTICLE

    Long Noncoding RNA PlncRNA-1 Promotes Colorectal Cancer Cell Progression by Regulating the PI3K/Akt Signaling Pathway

    Wei Song*, Jia-Zhuan Mei, Mingzhi Zhang

    Oncology Research, Vol.26, No.2, pp. 261-268, 2018, DOI:10.3727/096504017X15031557924132

    Abstract Accumulating evidence has indicated that long noncoding RNA (lncRNA) PlncRNA-1 plays an important regulatory role in cancers. However, the expression and biological functions of PlncRNA-1 in colorectal cancer (CRC) are still unclear. In the present study, we determined the expression of PlncRNA-1 in CRC and explored the function of PlncRNA-1 on CRC cell progression. The results showed that PlncRNA-1 was significantly increased in CRC tissues and cell lines; high PlncRNA-1 expression was associated with depth of invasion, lymph node metastasis, and TNM stage of CRC patients. Kaplan–Meier curve analysis showed that patients with high PlncRNA-1 More >

  • Open Access

    ARTICLE

    Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer

    Kazuyoshi Kawakami*, Takashi Yokokawa*, Kazuo Kobayashi*, Takahito Sugisaki*, Kenichi Suzuki*, Mitsukuni Suenaga, Kensei Yamaguchi, Ayaka Inoue, Yoshiaki Machida, Toshiharu Yamaguchi, Toshihiro Hama*

    Oncology Research, Vol.25, No.9, pp. 1625-1631, 2017, DOI:10.3727/096504017X15012905098071

    Abstract Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer. The main aims of this study were to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011, and April 30, 2015, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Our study assessed adherence… More >

  • Open Access

    ARTICLE

    Overexpression of Hepatocyte Cell Adhesion Molecule (hepaCAM) Inhibits the Proliferation, Migration, and Invasion in Colorectal Cancer Cells

    Hai-tao Geng*, Rui-juan Cao*, Lei Cheng, Chun-yuan Liu

    Oncology Research, Vol.25, No.7, pp. 1039-1046, 2017, DOI:10.3727/096504016X14813914187138

    Abstract Hepatocyte cell adhesion molecule (hepaCAM), a new type of CAM, belongs to the immunoglobulin superfamily. Recently, hepaCAM was reported to be implicated in cancer development, and many researchers investigated its biological function in the tumorigenesis of various cancers. However, what kind of role hepaCAM plays in colorectal cancer (CRC) remains unknown. In this study, we found that hepaCAM was downregulated in CRC tissues and cell lines. Overexpression of hepaCAM inhibited CRC cell proliferation, migration, and invasion in vitro. Furthermore, the tumorigenesis assay showed that increased expression of hepaCAM suppressed CRC tumor growth and metastasis in More >

Displaying 81-90 on page 9 of 102. Per Page